| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Androgen | 19 | 2020 | 407 | 3.390 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 1513 | 2.550 |
Why?
|
| Phosphoric Monoester Hydrolases | 6 | 2021 | 100 | 2.110 |
Why?
|
| Receptors, Peptide | 12 | 2024 | 47 | 1.900 |
Why?
|
| Receptors, G-Protein-Coupled | 14 | 2024 | 279 | 1.790 |
Why?
|
| Relaxin | 8 | 2024 | 15 | 1.600 |
Why?
|
| Androgens | 8 | 2016 | 256 | 0.990 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 32 | 0.820 |
Why?
|
| Infertility | 1 | 2022 | 90 | 0.740 |
Why?
|
| Cell Line, Tumor | 16 | 2020 | 3293 | 0.740 |
Why?
|
| Signal Transduction | 10 | 2021 | 4493 | 0.730 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2020 | 3 | 0.700 |
Why?
|
| Glycoside Hydrolases | 1 | 2020 | 17 | 0.690 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 1872 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 488 | 0.620 |
Why?
|
| Protein Kinase C | 2 | 2018 | 150 | 0.590 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 3 | 2016 | 54 | 0.590 |
Why?
|
| Prostate | 2 | 2018 | 421 | 0.550 |
Why?
|
| Cell Proliferation | 13 | 2020 | 2307 | 0.530 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2006 | 98 | 0.530 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2008 | 201 | 0.510 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 1702 | 0.500 |
Why?
|
| Metabolism | 1 | 2015 | 42 | 0.500 |
Why?
|
| DNA-Binding Proteins | 4 | 2018 | 2055 | 0.460 |
Why?
|
| Animals | 32 | 2024 | 33796 | 0.460 |
Why?
|
| Disease Progression | 7 | 2016 | 2028 | 0.450 |
Why?
|
| Reproduction | 1 | 2015 | 243 | 0.430 |
Why?
|
| Testis | 4 | 2022 | 405 | 0.430 |
Why?
|
| Gene Expression | 3 | 2016 | 1565 | 0.430 |
Why?
|
| Receptors, Progesterone | 3 | 2013 | 866 | 0.420 |
Why?
|
| Male | 31 | 2024 | 60089 | 0.410 |
Why?
|
| Histone Acetyltransferases | 3 | 2009 | 313 | 0.410 |
Why?
|
| HEK293 Cells | 6 | 2024 | 741 | 0.390 |
Why?
|
| Mice | 20 | 2024 | 17540 | 0.390 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 244 | 0.380 |
Why?
|
| Transcription Factors | 6 | 2009 | 2585 | 0.370 |
Why?
|
| Testosterone | 2 | 2015 | 465 | 0.370 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 340 | 0.360 |
Why?
|
| Ovarian Neoplasms | 8 | 2004 | 408 | 0.350 |
Why?
|
| Spermatogenesis | 2 | 2022 | 166 | 0.350 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 202 | 0.340 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 502 | 0.330 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 2524 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 96 | 0.300 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 482 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 113 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2011 | 1118 | 0.280 |
Why?
|
| Humans | 43 | 2024 | 123046 | 0.270 |
Why?
|
| Transfection | 7 | 2013 | 1068 | 0.240 |
Why?
|
| Cricetulus | 1 | 2024 | 97 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 353 | 0.230 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 2395 | 0.230 |
Why?
|
| CHO Cells | 1 | 2024 | 157 | 0.230 |
Why?
|
| Nitriles | 4 | 2016 | 145 | 0.230 |
Why?
|
| Protein Engineering | 1 | 2024 | 73 | 0.230 |
Why?
|
| Small Molecule Libraries | 3 | 2018 | 118 | 0.230 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 100 | 0.210 |
Why?
|
| Anilides | 3 | 2016 | 48 | 0.210 |
Why?
|
| Inositol Phosphates | 1 | 2022 | 12 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 313 | 0.210 |
Why?
|
| Metribolone | 4 | 2006 | 29 | 0.200 |
Why?
|
| Nuclear Receptor Coactivator 1 | 3 | 2009 | 242 | 0.200 |
Why?
|
| Androgen Antagonists | 3 | 2016 | 114 | 0.200 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 664 | 0.200 |
Why?
|
| Semen | 1 | 2022 | 75 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 269 | 0.200 |
Why?
|
| Thymidine Kinase | 6 | 1999 | 95 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 3 | 2012 | 33 | 0.190 |
Why?
|
| Transcriptome | 2 | 2018 | 903 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 653 | 0.180 |
Why?
|
| Protective Agents | 1 | 2021 | 31 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 5 | 2008 | 1339 | 0.170 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2019 | 1 | 0.170 |
Why?
|
| Drug Synergism | 1 | 2020 | 239 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2009 | 816 | 0.170 |
Why?
|
| Tosyl Compounds | 3 | 2016 | 21 | 0.160 |
Why?
|
| Genetic Therapy | 6 | 1999 | 678 | 0.160 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 62 | 0.150 |
Why?
|
| Adenoviridae | 6 | 1999 | 608 | 0.150 |
Why?
|
| Hepatic Stellate Cells | 1 | 2018 | 20 | 0.150 |
Why?
|
| Spermatozoa | 1 | 2020 | 231 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 4355 | 0.150 |
Why?
|
| COS Cells | 4 | 2012 | 273 | 0.150 |
Why?
|
| Benzamides | 1 | 2018 | 106 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 524 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 329 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 239 | 0.140 |
Why?
|
| Binding Sites | 4 | 2012 | 1292 | 0.140 |
Why?
|
| Gene Silencing | 2 | 2016 | 236 | 0.140 |
Why?
|
| DNA Repair | 1 | 2020 | 579 | 0.130 |
Why?
|
| Protein Binding | 2 | 2018 | 1741 | 0.130 |
Why?
|
| Neoplasms | 1 | 2011 | 2757 | 0.130 |
Why?
|
| Cell Movement | 4 | 2014 | 831 | 0.130 |
Why?
|
| RNA Interference | 2 | 2016 | 496 | 0.130 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 823 | 0.130 |
Why?
|
| Cyclic AMP | 2 | 2013 | 247 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 350 | 0.120 |
Why?
|
| Maleimides | 1 | 2014 | 12 | 0.120 |
Why?
|
| Introns | 2 | 2006 | 301 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 45 | 0.120 |
Why?
|
| High Mobility Group Proteins | 2 | 2007 | 32 | 0.120 |
Why?
|
| HeLa Cells | 3 | 2006 | 809 | 0.120 |
Why?
|
| Chromatin | 1 | 2018 | 554 | 0.120 |
Why?
|
| p21-Activated Kinases | 1 | 2014 | 58 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 3076 | 0.110 |
Why?
|
| Receptors, Calcitriol | 2 | 2005 | 71 | 0.110 |
Why?
|
| Mice, Knockout | 2 | 2020 | 3722 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 4 | 2016 | 752 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 158 | 0.110 |
Why?
|
| Models, Biological | 2 | 2011 | 1442 | 0.110 |
Why?
|
| Interleukin-8 | 1 | 2014 | 209 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 180 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2013 | 16 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 4285 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2014 | 570 | 0.110 |
Why?
|
| Apoptosis | 4 | 2020 | 1782 | 0.110 |
Why?
|
| Software | 1 | 2018 | 674 | 0.110 |
Why?
|
| Computational Biology | 1 | 2018 | 804 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 125 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 604 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 151 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 862 | 0.100 |
Why?
|
| Oncogenes | 1 | 2013 | 168 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2013 | 423 | 0.100 |
Why?
|
| Rats | 3 | 2016 | 3651 | 0.100 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2012 | 72 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 96 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 993 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1688 | 0.100 |
Why?
|
| Histones | 2 | 2020 | 527 | 0.090 |
Why?
|
| Female | 16 | 2015 | 65482 | 0.090 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 482 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 454 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2020 | 996 | 0.080 |
Why?
|
| Cyproterone Acetate | 1 | 2009 | 5 | 0.080 |
Why?
|
| Diet, High-Fat | 2 | 2021 | 211 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2012 | 747 | 0.080 |
Why?
|
| Butadienes | 1 | 2008 | 19 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2009 | 283 | 0.080 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 111 | 0.080 |
Why?
|
| Alleles | 1 | 2013 | 1603 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 138 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2009 | 90 | 0.080 |
Why?
|
| Acetylation | 1 | 2008 | 166 | 0.080 |
Why?
|
| Protein Stability | 1 | 2008 | 166 | 0.070 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 2 | 2009 | 37 | 0.070 |
Why?
|
| Ganciclovir | 2 | 1998 | 102 | 0.070 |
Why?
|
| Cytomegalovirus | 2 | 1999 | 269 | 0.070 |
Why?
|
| Thymidine | 1 | 2006 | 54 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2008 | 298 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 315 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2009 | 345 | 0.070 |
Why?
|
| RNA, Long Noncoding | 1 | 2009 | 208 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2006 | 674 | 0.070 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 15 | 0.070 |
Why?
|
| Base Sequence | 2 | 2008 | 3091 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2005 | 73 | 0.060 |
Why?
|
| Mice, Nude | 5 | 2010 | 694 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 74 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2004 | 180 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2006 | 99 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 174 | 0.060 |
Why?
|
| Cytokines | 2 | 2020 | 1284 | 0.060 |
Why?
|
| Hormones | 1 | 2004 | 190 | 0.060 |
Why?
|
| Exons | 1 | 2006 | 794 | 0.060 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 177 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 1061 | 0.050 |
Why?
|
| DAX-1 Orphan Nuclear Receptor | 1 | 2003 | 8 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2003 | 15 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 26 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2003 | 25 | 0.050 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 63 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 56 | 0.050 |
Why?
|
| Mifepristone | 1 | 2003 | 138 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 106 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2022 | 84 | 0.050 |
Why?
|
| Avian Sarcoma Viruses | 2 | 1999 | 32 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 548 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2809 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 1998 | 743 | 0.050 |
Why?
|
| Insulin | 2 | 2022 | 1200 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2016 | 3867 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2007 | 1522 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 1268 | 0.050 |
Why?
|
| Mutation | 2 | 2006 | 5769 | 0.050 |
Why?
|
| Receptors, LH | 1 | 2020 | 13 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2771 | 0.040 |
Why?
|
| Disorders of Sex Development | 1 | 2000 | 78 | 0.040 |
Why?
|
| Sperm Count | 1 | 2020 | 75 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2695 | 0.040 |
Why?
|
| Meiosis | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2019 | 170 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2018 | 1070 | 0.040 |
Why?
|
| Drug Stability | 2 | 2013 | 55 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 718 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 2481 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 49 | 0.040 |
Why?
|
| Acyclovir | 1 | 1998 | 45 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 267 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2013 | 567 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 368 | 0.030 |
Why?
|
| Leukocytes | 1 | 1998 | 206 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1997 | 35 | 0.030 |
Why?
|
| Telomere | 1 | 1998 | 206 | 0.030 |
Why?
|
| Organoids | 1 | 2019 | 277 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2016 | 391 | 0.030 |
Why?
|
| Macaca | 1 | 2016 | 62 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2016 | 239 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1290 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2009 | 1100 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 253 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1681 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 2 | 2007 | 79 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2007 | 861 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2007 | 1473 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2013 | 79 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2013 | 100 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2013 | 57 | 0.030 |
Why?
|
| Swine | 1 | 2016 | 1155 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 357 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 249 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 137 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 413 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 426 | 0.020 |
Why?
|
| Desmin | 1 | 2009 | 21 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 1661 | 0.020 |
Why?
|
| Caveolin 1 | 1 | 2009 | 46 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2009 | 49 | 0.020 |
Why?
|
| Adult | 3 | 2022 | 28972 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 318 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 697 | 0.020 |
Why?
|
| Leydig Cells | 1 | 2007 | 20 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 455 | 0.020 |
Why?
|
| Integrases | 1 | 2007 | 161 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 113 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 1997 | 369 | 0.020 |
Why?
|
| Calcium Channel Agonists | 1 | 2005 | 12 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 371 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 123 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 94 | 0.020 |
Why?
|
| Cell Survival | 2 | 1998 | 808 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 113 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 137 | 0.020 |
Why?
|
| Calcitriol | 1 | 2005 | 80 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 1610 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 330 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 458 | 0.020 |
Why?
|
| Ligands | 1 | 2006 | 533 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 253 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 3040 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 256 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 780 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1679 | 0.010 |
Why?
|
| Genetic Vectors | 2 | 1999 | 940 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2002 | 52 | 0.010 |
Why?
|
| Threonine | 1 | 2002 | 59 | 0.010 |
Why?
|
| Alanine | 1 | 2002 | 180 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 347 | 0.010 |
Why?
|
| Proteins | 1 | 2007 | 1037 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 194 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 833 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2000 | 147 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2000 | 251 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 473 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 660 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 757 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1999 | 104 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 527 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 1081 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 1576 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 720 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 696 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 4512 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 570 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 25972 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 12109 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 1236 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 1588 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 2799 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 4226 | 0.010 |
Why?
|
| Aged | 1 | 1998 | 19083 | 0.000 |
Why?
|